ClinicalTrials.gg
RecruitingNCT07488897Updated Sep 9, 2026

RIG 101 Trial in Healthy Adults and Adults With Asthma

A Phase 1/2 interventional study of RIG-101 and Placebo in Healthy Adult Participants, Asthma Exacerbation and Safety and Efficacy, sponsored by RIGImmune Inc.. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by RIGImmune Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 558 studies in Asthma with a site in United Kingdom — 52 open to participants now, 71 under way, 11 of them phase 3. Asthma · United Kingdom.

Planned enrollment
201st of 427
82 · median 69
Started
2026
with 16 others
Phase 1/2
6 of 558
1 open now
Primary completion
2027-02
later than 30 of 70 live
Registered
548th of 558
by date

Among the 558 studies in Asthma with a site in United Kingdom, this one is the 201st largest by planned enrollment of the 427 interventional ones that give a count, is one of 17 that started in 2026, is one of 6 in phase 1/2, reaches primary completion later than 30 of the 70 other live ones, and was the 548th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

52 of the 558 studies in Asthma with a site in United Kingdom are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 558 studies in Asthma with a site in United Kingdom, or all of them as a file.
02

Study summary

Nested Phase 1-2 Trial of RIG-101 in Healthy and Asthmatic Participants Assessing Safety, Tolerability and Viral Challenge Efficacy

03

Conditions studied

  • Healthy Adult Participants
  • Asthma Exacerbation
  • Safety and Efficacy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Participants must meet all the following inclusion criteria to be eligible to participate in the trial.

  • Participants must have a written obtained prior to any trial related procedure
  • Male and female participants aged between 18 to 65 years inclusive, at the time of informed consent.
  • Participants must be in good health as determined by medical history, physical examination, vital signs, 12-lead and clinical laboratory assessments at the time of screening, as judged by the Investigator.

Additional Inclusion Criteria for Healthy Participants

- Participants must have a pre-bronchodilator ≥80% predicted (using GLI Global predicted values17) and an FEV1 / FVC ratio of >70% absolute at screening.

Additional Inclusion Criteria for Participants with Asthma

  • Participants must have a clinical diagnosis of asthma.
  • Participants must have either a positive skin prick test with a wheal diameter of ≥3mm greater than control test at 15 minutes, and/or a blood eosinophil count of > 200 cells / µL and/or a FeNO level of > 25 ppb at screening.
  • Participants must have a pre-bronchodilator FEV1 ≥65% predicted at screening
  • Participants must be using SABA alone or inhaled (ICS) with SABA or ICS with formoterol as reliever therapy, AND/OR regular use of low to mid-dose ICS with or without LABA at a stable dose for at least 3 months prior to randomization to control their asthma.

Part B only

  • Participants must have an ACQ-6 score of > 0.75 at screening.
  • Participants must have a history of asthma worsening in the previous 2 years, in response to a cold or respiratory infection, as confirmed by the participant.
  • Participants must demonstrate seronegativity to RV-A16

Exclusion Criteria:

Exclusion Criteria for all Participants

  • History or presence of any acute or chronic medical or psychiatric condition that could interfere with the participant's safety during the clinical trial, expose the participant to undue risk or interfere with the participants ability to successfully conduct the trial, as judged by the Investigator.
  • Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the trial at time of screening.
  • Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first administration of IMP and/or history of being hospitalized due to epistaxis on any previous occasion.
  • Any nasal or sinus surgery within 3 months of the first administration of IMP
  • Any signs of upper respiratory tract infection within 6 weeks of screening or prior to first administration of IMP
  • Current or previous use of tobacco, nicotine products or e-cigarettes in the past 6 months prior to screening.
  • Smoking history of > 5 pack years.

Additional Exclusion Criteria for Participants with Asthma

  • Any asthma exacerbation on their current asthma controller medication requiring oral/systemic corticosteroids within 8 weeks of randomization, or that resulted in overnight hospitalization requiring additional treatment for asthma within 3 months of randomization.
  • Difficult-to-treat or severe asthma requiring the maintenance use of add-on biologic Type 2 targeted treatments including anti-Immunoglobulin E, anti-IL4 receptor, anti-IL5, anti-IL5 receptor, and anti-Thymic Stromal Lymphopoietin
  • History of life-threatening asthma, defined as any asthma episode that required admission to a high-dependency or intensive therapy unit.
  • Individuals with close contact to at risk patient groups
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
82 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Other: Placebo

  • Experimental
    RIG-101

    Drug: RIG-101

Interventions

  • DrugRIG-101

    Single, and repeat escalating intranasal administrations of RIG-101

  • OtherPlacebo

    Single and repeat Intranasal administrations

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs) and Serious Adverse Events (SAEs)

    All adverse events (AEs) and serious adverse events (SAEs) will be collected using standard regulatory AE/SAE monitoring procedures. Events will be assessed for severity and relationship to intranasal RIG-101 according to protocol-defined criteria. Data will be recorded from the signing of informed consent through the follow-up visit.

    Time frame: Day 1-35

  2. Systolic/Diastolic blood pressure

    Systolic/Diastolic blood pressure will be measured after participants rest in a supine position for ≥5 minutes. Unit of Measure: Change from baseline mmHg

    Time frame: Day 0 - 35

  3. Physical examinations

    Physical examinations-general and system-specific (cardiovascular, respiratory, ENT, lymphatic, neurological, abdominal, musculoskeletal, dermatologic)-will be performed per protocol. Findings will be categorized as normal or abnormal, with clinical significance determined by the investigator. Unit of Measure: Incidence of clinically significant physical exam abnormalities

    Time frame: Day 0 -35

  4. Nasal examinations

    Nasal examinations are performed to identify structural anomalies, inflammation, or other abnormalities in the anterior nares. Unit of Measure: Incidence of nasal exam abnormalities

    Time frame: Day 0 - 35

  5. Spirometry (FEV₁ and FVC)

    Spirometry (FEV₁ and FVC) will be conducted per ATS/ERS 2019 standards. Predicted values will use the GLI global dataset. Unit of Measure: Change from baseline in litres Measurement Tool: ATS/ERS-compliant spirometers

    Time frame: Day 0-35

  6. Triplicate 12-lead ECGs and single 12-lead ECGs

    Triplicate 12-lead ECGs and single 12-lead ECGs will be collected after ≥5 minutes of supine rest. Parameters include HR, PR interval, QRS duration, QT, and QTcF. Unit of Measure: Change from baseline in ECG parameters

    Time frame: Day 0 - 35

  7. Safety laboratory testing-haematology

    Safety laboratory testing-haematology, will be assessed per protocol and judged for clinical significance. Unit of Measure: Change in parameters of haematology laboratory values assessed using local lab reference ranges

    Time frame: Day 0 - 35

  8. Safety laboratory testing-Serum Chemistry

    Safety laboratory testing-Serum chemistry, will be assessed per protocol and judged for clinical significance. Unit of Measure: Change in parameters of Serum chemistry laboratory values assessed using local lab reference ranges

    Time frame: Day 0- 35

  9. Safety laboratory testing-Coagulation

    Safety laboratory testing-Coagulation will be assessed per protocol and judged for clinical significance. Unit of Measure: Change in parameters of Coagulation laboratory values assessed using local lab reference ranges

    Time frame: Day 0 -35

  10. Lower respiratory tract symptom score assessments

    Participants complete twice-daily LRSS assessments for 35 days. The primary endpoint is the total symptom burden expressed as area under the curve (AUC) for LRSS from baseline through Day 35. Unit of Measure: AUC (LRSS × days) Measurement Tool: Twice-daily electronic diary (eDiary) symptom scoring system

    Time frame: Day -7 to 35

  11. AUC of Lower respiratory tract symptom score

    AUC of LRSS where the lower respiratory symptoms are measured for 35 days by twice-daily date and time stamped eDiary collection

    Time frame: Day -7 to 35

  12. Vital Signs - heart rate

    Heart rate will be measured after participants rest in a supine position for ≥5 minutes. Unit of Measure: Change from baseline BPM

    Time frame: Day 0 - 35

07

Study locations

2 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 23, 2026
StartActual
Feb 9, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07488897
Lead sponsor
RIGImmune Inc.
Collaborators
Virtus Respiratory Research, Medicines Evaluation Unit Ltd
Responsible party
Sponsor
First posted
Mar 23, 2026
Start date
Feb 9, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion